Last mentioned: Mar 18, 2026
PDUFA Date
Target date for FDA decision on INO-3107 accelerated approval.
Platform Modernization
LivePerson expects to complete its multiyear platform modernization.
BLA Acceptance
FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.
Inovio Cash Position
Company ends the year with $94.1 million in cash.
LivePerson reported Q4 2025 earnings beating expectations, driven by a significant shift toward generative AI integration across its conversational platform. While the company faces sequential revenue declines, the launch of the Syntrix platform and strong adoption of AI-powered tools signal a fundamental transition in its business model.
LivePerson exceeded Q4 2025 expectations with $59.3 million in revenue and $10.8 million in Adjusted EBITDA, driven by the commercial launch of its Syntrix platform and aggressive cost discipline. While total revenue continues a sequential decline due to legacy churn, the company is betting on a unified AI architecture and high-value enterprise expansions to return to growth by late 2026.
Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.